TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02642809

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography-guided biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Study: NCT01834027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jazz music
Description: Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No music
Description: In this group no music will be played in PACU
Study: NCT01971645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
Study: NCT03510663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 16mg
Description: OPC-61815 16mg will be intravenously administered once a week.
Study: NCT00260078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg orally daily
Study: NCT03510663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815 32mg
Description: OPC-61815 32mg will be intravenously administered once a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg tablet will be administrated once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo will be intravenously administered once a week.
Study: NCT01671436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Central Meditation and Imagery Therapy
Study: NCT02976493

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT04003636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine by IV infusion
Study: NCT03227575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
Study: NCT00260078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300 mg orally daily

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
Study: NCT01629706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lens
Description: Commercially marketed silicone hydrogel contact lens
Study: NCT06169436

Intervention type: PROCEDURE
Intervention: Nephroureterectomy
Description: Removal of cancer mass by urether and kidney complete resection.
Study: NCT01047943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical application of STA-21 ointment for treatment of psoriasis
Study: NCT01629706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual contact lenses
Description: Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renu multi-purpose solution
Description: Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
Study: NCT02059642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MG01CI (1400 mg)
Description: MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 1400 mg administered orally once daily
Study: NCT02207101

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E-OJ-01 (OXYJUN)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05943990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3845097
Description: GSK3845097 was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide was administered as lymphodepleting chemotherapy.
Study: NCT04724174

Intervention type: PROCEDURE
Intervention: pancreaticogastrostomy
Description: Pancreaticogastrostomy technique was performed according to the precise description of Addeo et al.

Intervention type: PROCEDURE
Intervention: pancreaticojejunostomy
Description: Pancreaticojejunostomy technique was performed using the 5/0 polypropylene interrupted monofilament suture in a one-layered duct-to-mucosa end-to-side anastomosis (Cattell-Warren anastomosis).
Study: NCT05943990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine was administered as lymphodepleting chemotherapy.
Study: NCT03508700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL 5.6 mg
Description: cyclobenzaprine HCl sublingual tablets
Study: NCT03812172

Intervention type: DRUG
Intervention: 99mTc-PYP or 99m Tc-HDP
Description: 10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
Study: NCT03278340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sun Safe Workplaces - Technology
Description: After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
Study: NCT04422821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring
Description: Flash Glucose Monitoring FreeStyle Libre™ (Abbott Diabetes Care, Alameda, CA) sensor placed subcutaneously that will be applied for 14 days, then removed and changed for the second sensor for the next 14 days.
Study: NCT04003636

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin by IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab
Study: NCT02987673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MGB/OAGB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSG
Study: NCT01553539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic angiotensin-(1-7)
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT01659944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Tablets for oral administration
Study: NCT00514449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: 1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
Study: NCT01651260

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental ET Tube Securement Device
Description: Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
Study: NCT01463852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
Study: NCT00170157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Given orally
Study: NCT03278340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sun Safe Workplaces -In Person
Description: After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
Study: NCT01629706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearCare
Description: Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual lens care
Description: Lens care per habitual use
Study: NCT02117414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan sequences of the head and chest regions
Description: Non-diagnostic MRI scans
Study: NCT00170157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative study
Study: NCT03078673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training intervention, motor skill training
Description: cross country specific motor skill strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training intervention, maximal strength training
Description: general maximal strength training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: regular training
Study: NCT00805883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Phothtermal Ablation
Description: Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
Study: NCT01832311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
Study: NCT02595060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled molgramostim (rhGM-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled molgramostim (rhGM-CSF)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled placebo
Description: formulated as the active substance without molgramostim
Study: NCT03184701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
Study: NCT02540174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: integrated addiction treatment program
Description: At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard of care
Description: The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~* At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~* At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption
Study: NCT00003530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03837756

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study: NCT02117414

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Waiting Period Visit
Description: Waiting period time will equate to 1 hour
Study: NCT01546064

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Choledocho-choledochostomy with T-tube
Description: In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Choledocho-choledochostomy without T-tube
Description: The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
Study: NCT03158714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Connecting Mindfully

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELEVATE
Study: NCT03962309

Intervention type: OTHER
Intervention: Health self-assessment questionnaire
Description: The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
Study: NCT02537574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX/BUP
Description: Daily doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTX/PBO-B
Description: Daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PBO-N/PBO-B
Description: Daily doses
Study: NCT04161300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam Rolling (FR)
Description: FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (CG)
Description: The CG did not receive any intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic Manual Physical Therapy Group (OMPT)
Description: Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
Study: NCT02663687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 esterase inhibitor
Description: Subjects will receive escalating doses I-IV as both IV and SC injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP623
Description: SHP623

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04661553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mueller's polarimetric colposcopy Group 1
Description: Determination of the best polarimetric biomarkers reflecting the status of the cervical microstructure throughout its remodeling process due to the pregnancy in a population with a low-risk premature birth. This polarimetric biomarkers should make it possible to accurately determine the time remaining before childbirth for a normal pregnancy and, therefore, to monitor the regular advancement of the gestation.
Study: NCT02375815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin Choice Implementation
Study: NCT03849846

Intervention type: OTHER
Intervention: Focus groups
Description: Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
Study: NCT04584073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application
Description: Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application
Description: Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenoidectomy alone or with Myringotomy or with Myringotomy and Tympanostomy Tube application
Description: Adenoidectomy with or without tonsillectomy when indicated will be performed. simple Myringotomy incision will be done in the antero-inferior quadrant of pars tensa of both tympanic membranes. Middle ear fluids will be aspirated. Tympanostomy tube application will be done.
Study: NCT04422821

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Monitoring of Blood Glucose
Description: Self-Monitoring of Blood Glucose with a standard glucose meter (iXell®; Genexo sp; Warsaw, Poland) performed through a skin-puncturing 4 times a day for 28 days.